Granules ties up with GSK Healthcare R&D

Granules India Ltd has signed its first Master Services Agreement with GlaxoSmithKline Consumer Healthcare R&D for product development recently.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney
moneycontrol.com

Home » News » Business

Jan 20, 2007, 11.29 AM | Source: Moneycontrol.com

Granules ties up with GSK Healthcare R&D

Granules India Ltd has signed its first Master Services Agreement with GlaxoSmithKline Consumer Healthcare R&D for product development recently.

Like this story, share it with millions of investors on M3

Granules ties up with GSK Healthcare R&D

Granules India Ltd has signed its first Master Services Agreement with GlaxoSmithKline Consumer Healthcare R&D for product development recently.

Post Your Comments

Share Cancel

Hyderabad , Jan. 19

Granules India Ltd has signed its first Master Services Agreement with GlaxoSmithKline Consumer Healthcare R&D for product development recently.

The agreement is part of the company's venture into contracts for product development with various partner companies, according to Mr Krishna Prasad, Managing Director.

The Hyderabad-based pharmaceutical formulation intermediates (PFIs) company has reported a 37.43 per cent jump in net profit at Rs 3.05 crore for the quarter ended December 31, 2006 against Rs 2.22 crore in the corresponding quarter last year.

Net sales during the quarter grew by 12.98 per cent to Rs 50.21 crore, compared with Rs 44.44 crore in the corresponding quarter of last fiscal.

Explaining the company's performance, Mr Krishna Prasad said Metformin API (active pharmaceutical intermediates) and PFIs have largely contributed to the growth. During the review period, Granules India also signed a memorandum of understanding with Hubei Biocause Hellen Pharmaceutical Company (Biocause) of China. It acquired a 50 per cent stake in the company to manufacture APIs, starting with Ibuprofen, of which Biocause is one of the biggest manufacturers and exporters globally.

The company also signed an MoU with PharmaMatch to develop, manufacture and market formulations in the European market jointly.

Taken from Business Line

thehindubusinessline.in

Buy, Hold, Sell ? Hear it first on M3
Granules ties up with GSK Healthcare R&D

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login